Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    790 result(s) found for: Cyclophosphamide. Displaying page 4 of 40.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-003829-16 Sponsor Protocol Number: RV-MM-DSMM-0279 Start Date*: 2009-09-15
    Sponsor Name:GMIHO - Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH
    Full Title: An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide...
    Medical condition: relapsed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004969-27 Sponsor Protocol Number: 69HCL17_0028 Start Date*: 2018-05-28
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A multicenter randomized open-label trial comparing the efficacy and safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis CIRIS: Cyclophosphamide vs. Infli...
    Medical condition: anterior idiopathic scleritis or anterior and posterior idiopathic scleritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10039705 Scleritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000052-17 Sponsor Protocol Number: PK201301 Start Date*: 2013-10-07
    Sponsor Name:The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation
    Medical condition: Ewing sarcoma patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002129-12 Sponsor Protocol Number: P150955 Start Date*: 2016-10-12
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A randomized phase IIb study of cyclophosphamide (Cy) versus anti-thymocyte globulin (ATG) for the prophylaxis of graft-versus-host disease (GVHD) after reduced-intensity conditioning allogeneic pe...
    Medical condition: Women and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicated
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10053239 Prophylaxis against graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003678-29 Sponsor Protocol Number: PERSPECTIVE Start Date*: 2014-03-31
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and dexamethasonE in RelapSed myeloma Plus rEsponse adapted Cyclophosphamide as a Tailored InnoVativE strategy
    Medical condition: Relapsed and refractory multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005155-32 Sponsor Protocol Number: COSYMO Start Date*: 2014-12-12
    Sponsor Name:Leiden University Medical Center
    Full Title: A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.
    Medical condition: Conventional chondrosarcoma Myxoid liposarcoma with PIK3CA mutation or PTEN loss Mesenchymal or dedifferentiated chondrosarcoma Clear cell chondrosarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005453-38 Sponsor Protocol Number: SuccessC-Trial Start Date*: 2008-12-17
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies SUCCESS C-Trial
    Medical condition: Patients with primary epithelial invasive carcinoma of the breast pT1-4, pN0-3, pM0
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003459-31 Sponsor Protocol Number: 2016/816 Start Date*: 2016-10-10
    Sponsor Name:Helse Bergen, Haukeland University Hospital
    Full Title: Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - the p53 trial
    Medical condition: Locally advanced breast cancer and metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020835-38 Sponsor Protocol Number: IEOS550310 Start Date*: 2011-09-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: “A phase II study of cisplatin plus cyclophospamide for patients with previously treated, advanced, triple receptor negative breast cancer”
    Medical condition: Advanced, triple receptor negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003789-15 Sponsor Protocol Number: NMSG#20/13 Start Date*: 2014-01-08
    Sponsor Name:Nordic Myeloma Study Group
    Full Title: Phase II study of carfilzomib- cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observa-tion or maintenance with carfil-zomib and dexamethasone in pa-tients ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) SE (Completed) NO (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001432-22 Sponsor Protocol Number: IC2013-05 Start Date*: 2014-07-25
    Sponsor Name:INSTITUT CURIE
    Full Title: A Multicenter Open label Phase II study of Pomalidomide and Cyclophosphamide and Dexamethasone in relapse/refractory Multiple Myeloma patients who were first treated within the IFM/DFCI 2009 trial
    Medical condition: Progressive/Refractory multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004604-35 Sponsor Protocol Number: ICONMM Start Date*: 2020-06-17
    Sponsor Name:VU University Medical Center
    Full Title: A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IberCd): ICON study
    Medical condition: Relapsed/refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000309-75 Sponsor Protocol Number: Start Date*: 2005-08-26
    Sponsor Name:Christian Geisler, Rigshospitalet, dept. Haematology 4042
    Full Title: HOVON 68 CLL: A randomized phase III study in prevously untreated patients with biological high risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.
    Medical condition: Chronic lymphocytic leukaemia (CLL) in biological high-risk group: Unmutated and/or with deletion 17p and/or deletion 11q and/or trisomy 12.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Ongoing) FI (Completed) BE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001226-25 Sponsor Protocol Number: HD-TNBC-TRIAL Start Date*: 2015-04-20
    Sponsor Name:ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple ne...
    Medical condition: Triple Negative Breast Cancer patients with breast tumor >2,5 cm
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004511-36 Sponsor Protocol Number: HM13/10993 Start Date*: 2015-09-28
    Sponsor Name:University Of Leeds
    Full Title: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with tha...
    Medical condition: Relasped and Refractory Mulitple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-003902-27 Sponsor Protocol Number: 26866138MMY2031 Start Date*: 2006-02-13
    Sponsor Name:ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH
    Full Title: Clinical trial on induction of remission with bortezomib (Vel), cyclophosphamide (C) and dexamethasone (D) in patients until the age of 60 with untreated multiple myeloma and planned high dosage ch...
    Medical condition: Untreated patients with cytologically and/or histologically established multiple myeloma (Durie and Salmon stage II or III) requiring treatment with measurable myeloma protein in the blood or urine.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002751-34 Sponsor Protocol Number: 8050 Start Date*: 2011-10-13
    Sponsor Name:Vejle Hospital
    Full Title: An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Di...
    Medical condition: Patients with newly diagnosed symptomatic multiple myeloma according to the International Myeloma Working Group Diagnostic Criteria (Kyle 2009)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000173-77 Sponsor Protocol Number: 2013-000173-77 Start Date*: 2014-02-12
    Sponsor Name:Institut Jules Bordet
    Full Title: TRIUMPH Trial A phase II TRial evalUating the Menstrual and ovarian function of young breast cancer patients treated with a cycloPHosphamide-free regimen composed of doxorubicin and paclitaxel
    Medical condition: Primary breast cancer (adjuvant or neoadjuvant)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003995-23 Sponsor Protocol Number: GBG52 Start Date*: 2009-03-31
    Sponsor Name:GBG Forschungs GmbH
    Full Title: An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an in...
    Medical condition: Primary breast cancer at non-frail, eldery male and female patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004800-23 Sponsor Protocol Number: RG-17-241 Start Date*: 2018-06-12
    Sponsor Name:University of Birmingham
    Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co...
    Medical condition: Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:26:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA